Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 1/20 | 0.51 |
| ▸ | SIGLEC9 | Q9Y336 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6345789 | 0.89 | EPHX2 (0.56) | SIGLEC9EPHX2GRIN2BCYP3A4CYP2D6 | |
| SCHEMBL6343564 | 0.85 | NOS2 (0.61) | NOS2EPHX2EGFRBTKGRIN2B | |
| SCHEMBL6985709 | 0.77 | SIGLEC9 (0.45) | SIGLEC9EPHX2SCD | |
| SCHEMBL6355548 | 0.77 | CYP2D6 (0.48) | NOS2EPHX2GRIN2BCYP2D6CYP2C9 | |
| SCHEMBL6987185 | 0.75 | SIGLEC9 (0.45) | SIGLEC9EPHX2C3AR1SCDDRD2 | |
| SCHEMBL6346657 | 0.74 | SCD (0.56) | EPHX2GRIN2BCYP2C9SCD | |
| SCHEMBL6356500 | 0.73 | EPHX2 (0.53) | NOS2EPHX2GRIN2BSCD | |
| SCHEMBL6347296 | 0.73 | SIGLEC9 (0.49) | NOS2SIGLEC9EPHX2EGFRBTK | |
| Hydrochloric Acid SCHEMBL6983385 | 0.72 | SIGLEC9 (0.40) | SIGLEC9EPHX2BTKSCD | |
| SCHEMBL23013515 | 0.72 | SIGLEC9 (0.57) | SIGLEC9EPHX2EGFRBTKGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878725-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040242656-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-12-02 | — | — | US | disclosed |
| EP-1289950-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030078438-A1 | Serine protease inhibitors | ELI LILLY AND COMPANY | 2003-04-24 | — | — | US | disclosed |
| EP-1289950-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001096296-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078438-A1 | Serine protease inhibitors | HPN, LPXN, PRSS1 | NOS2 3577/4885SIGLEC9 667/4885EPHX2 1259/4885 |
| US-20040242656-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | NOS2 3536/4885SIGLEC9 925/4885EPHX2 1576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.